KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) increased 20.00% to close at $0.660 in the last trading session and its total traded volume was 2.92 million shares versus average volume of 1.78 million. The company has market cap of $18.11 million while its total outstanding shares are 32.92 million. KaloBios Pharmaceuticals Inc (KBIO), publicized that it will present at the 14th Annual Needham Healthcare Conference in New York City, New York on April 14, 2015. Herb Cross, Interim Chief Executive Officer and Chief Financial Officer of KaloBios, will offer an update on the company’s KB004 (anti-EphA3 mAb) program to treat hematologic malignancies and with the potential to treat solid tumors.
Herb Cross, Interim Chief Executive Officer and Chief Financial Officer of KaloBios, will provide an update on the company's KB004 (anti-EphA3 mAb) program to treat hematologic malignancies and with the potential to treat solid tumors. This program is currently in the Phase 2 expansion portion of its Phase 1/2 study, enrolling patients with myelodysplastic syndrome or myelofibrosis.
Willy-Short..... you are vry short of brain.... this one finally will be over $1 this week.... you have not a clue
good luck to longs
LUDWICK.MARK you can not delete the false statement.... message is in Yahoo BB and a copy is in the SEC office. You will hear from the authorities for this delictive practice in Internet.